×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XFOR – x4 pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XFOR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
08:15 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Medium
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
3/26
10:27 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
Low
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $3.00 price target on the stock.
3/25
06:10 am
xfor
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/25
06:01 am
xfor
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
High
Report
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/11
08:00 am
xfor
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
Low
Report
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
2/19
07:55 am
xfor
X4 Pharmaceuticals partners with taiba rare for distribution of XOLREMDI drug [Seeking Alpha]
Low
Report
X4 Pharmaceuticals partners with taiba rare for distribution of XOLREMDI drug [Seeking Alpha]
2/19
07:35 am
xfor
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Low
Report
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
2/7
08:28 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Low
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
06:07 am
xfor
x4 pharmaceuticals, inc.
MISS
Report
-57.8%
x4 pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
06:13 am
xfor
Form S-8 X4 Pharmaceuticals, Inc
Medium
Report
Form S-8 X4 Pharmaceuticals, Inc
3/26
06:01 am
xfor
Form 10-K X4 Pharmaceuticals, Inc For: Dec 31
Medium
Report
Form 10-K X4 Pharmaceuticals, Inc For: Dec 31
3/25
07:51 am
xfor
Form 8-K X4 Pharmaceuticals, Inc For: Mar 25
High
Report
Form 8-K X4 Pharmaceuticals, Inc For: Mar 25
3/24
04:43 pm
xfor
Form DEF 14A X4 Pharmaceuticals, Inc For: Mar 24
High
Report
Form DEF 14A X4 Pharmaceuticals, Inc For: Mar 24
3/14
04:07 pm
xfor
Form PRE 14A X4 Pharmaceuticals, Inc For: Mar 14
Medium
Report
Form PRE 14A X4 Pharmaceuticals, Inc For: Mar 14
3/3
05:03 pm
xfor
Form 8-K X4 Pharmaceuticals, Inc For: Mar 03
Low
Report
Form 8-K X4 Pharmaceuticals, Inc For: Mar 03
2/14
04:09 pm
xfor
Form 4 X4 Pharmaceuticals, Inc For: Feb 12 Filed by: Arbet-Engels Christophe
Medium
Report
Form 4 X4 Pharmaceuticals, Inc For: Feb 12 Filed by: Arbet-Engels Christophe
2/14
04:09 pm
xfor
Form 4 X4 Pharmaceuticals, Inc For: Feb 12 Filed by: Mostafa Adam S.
Medium
Report
Form 4 X4 Pharmaceuticals, Inc For: Feb 12 Filed by: Mostafa Adam S.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating.
33.7%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
2/8 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 13.1%
2/14 Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: Cormorant Asset Management, LP 10.5%
4/1 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8.4%
7/30 X4 Pharmaceuticals Receives Orphan Drug Designation from European Commission for Mavorixafor for Treatment of WHIM Syndrome 8.2%
6/7 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 7.5%
4/9 X4 Pharmaceuticals to Present and Participate in the Virtual 19th Annual Needham Healthcare Conference 7.3%
12/23 X4 Pharmaceuticals Inc (NASDAQ: XFOR) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $20.00 price target on the stock. 5.8%
11/10 X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.7%
2/28 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 5.3%
TOP News Decliners
3/20
Form 8-K X4 Pharmaceuticals, Inc For: Mar 18
-29.5%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
4/1 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -18.3%
3/17 Form 8-K X4 Pharmaceuticals, Inc For: Mar 13 -17.5%
11/26 X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants -16.8%
3/26 X4 Pharmaceuticals Inc (NASDAQ: XFOR) had its price target lowered by analysts at Citigroup Inc from $16.00 to $15.00. They now have a "buy" rating on the stock. -15.8%
9/20 Form 8-K X4 Pharmaceuticals, Inc For: Sep 18 -12.4%
3/13 Form S-8 X4 Pharmaceuticals, Inc -12.1%
5/17 Form 8-K/A X4 Pharmaceuticals, Inc For: Mar 29 -9.0%
9/14 X4 Pharmaceuticals Inc (NASDAQ: XFOR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.5%
5/15 X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia -7.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: